scholarly journals Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment

2021 ◽  
Vol 11 ◽  
Author(s):  
Bo Fan ◽  
Alradhi Mohammed ◽  
Yuanbin Huang ◽  
Hong Luo ◽  
Hongxian Zhang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Bladder Cancer ◽  
Case Control Study ◽  
Meta Analysis ◽  
Case Control ◽  
Female Patients ◽  
Kaplan Meier ◽  
History Of ◽  
The Impact ◽  
Control Study

Aspirin, widely used to prevent cardiovascular disease, had been linked to the incidence of bladder cancer (BCa). Existing studies focusing on Chinese populations are relatively rare, especially for Northeast China. Meanwhile, relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. First, in the case control study, logistic regression analysis was used to investigate the association between aspirin intake and risk of BCa including 1121 patients with BCa and the 2242 controls. Subsequently, Kaplan-Meier curve and Cox regression analyses were applied to explore the association between aspirin intake and clinicopathological factors which may predict overall survival (OS) and recurrence-free survival (RFS) of BCa patients. Finally, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence, outcome of surgery and prognosis of BCa by meta-analysis up to May 1, 2021.Our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa (P=0.175). Stratified analyses of sex showed that aspirin intake did not lead to a lower risk of BCa in female patients (P=0.063). However, the male population who regularly took aspirin had a lower incidence of BCa (OR=0.748, 95% CI= 0.584-0.958, P=0.021). Subgroup analyses stratified by smoking found a significant reduction in the risk of BCa in current smokers with aspirin intake (OR=0.522, 95% CI=0.342-0.797, P=0.002). In terms of prognosis of BCa, patients with a history of aspirin intake did not had a markedly longer OS or RFS than those with no history of aspirin intake by Kaplan-Meier curves. Stratified analysis by sex showed no correlation between aspirin intake and the recurrence or survival of BCa for either male or female patients. However, in people younger than 68, aspirin intake seemed to have prolonged effects for overall survival (HR=3.876; 95% CI=1.326-11.325, P=0.019). Then, we performed a meta-analysis and the combined results from 19 articles and our study involving more than 39524 BCa cases indicated that aspirin intake was not associated with the occurrence of BCa (P=0.671). Subgroup analysis by whether regular use of aspirin, by the mean duration of use of aspirin, by sex, by smoking exposure, by research region and by study type also supported the above results. In terms of the impact of aspirin intake on the prognosis of patients with BCa, 11 articles and our study involving 8825 BCa cases were eligible. The combined results showed that patients with aspirin intake did not have significantly influence on survival, recurrence, progression and metastasis than those without aspirin intake. On the whole, both our retrospective study and literature meta-analysis suggested a lack of a strong relevant association between the use of aspirin and the incidence or prognosis of BCa. Thus, additional long-term follow-up prospective research is warranted to clarify the association of aspirin with BCa incidence and prognosis.

Implications of pancreatic cancer with diabetes mellitus on patient outcomes and care: A matched case-control study.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 239-239
Author(s):  
Nina J. Karlin ◽  
Shailja Amin ◽  
Matthew Buras ◽  
Heidi E. Kosiorek ◽  
Patricia M. Verona ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Glycemic Control ◽  
Cancer Diagnosis ◽  
Case Control Study ◽  
Case Control ◽  
Kaplan Meier ◽  
The Impact ◽  
Control Study ◽  
Over Time

239 Background: The aim of this case-control study was to determine the impact of DM on survival in pancreatic cancer patients, and to examine the impact of pancreatic cancer on glycemic control in DM. Methods: Ninety-two patients with newly diagnosed pancreatic cancer from 2007 to 2015 with DM were identified from the institutional Cancer Registry and matched to ninety-two pancreatic cancer patients without DM according to age, gender, and year of pancreatic cancer diagnosis. The file was linked to the electronic medical record to obtain information on DM and pancreatic cancer therapies, and laboratory results. Overall survival (OS) was estimated with the Kaplan-Meier method and compared by Cox regression analysis. Mixed models were used to compare hemoglobin A1c (HbA1c) and glucose over time. Results: Mean age of the entire pancreatic cancer cohort was 70 years, most (92%) were white, most common (88%) histology was adenocarcinoma, and majority (41%) were stage IV. No differences in age, race/ethnicity, histology, or tumor stage were detected between patients with and without DM, although DM patients had higher body mass index (P = 0.014). Mean ca 19-9 (U/ml) was 804 for diabetics, and 395 for non-diabetics. Among those with DM the mean HbA1c during the year following cancer diagnosis was 7.3%. Time (days since diagnosis) was significant in DM patients (p = 0.014) as HbA1c decreased over time. Mean glucose during the year following diagnosis among DM patients was significantly higher compared to non-DM patients [160.6 (SD = 38.0) versus 117.2 (SD = 19.0); p < 0.001]. Both groups had a decline in glucose over time (p = 0.008). In Kaplan-Meier survival analysis (median follow-up time of 11.9 months), 2 year overall survival was estimated at 15% [95% CI: 8-24%] for DM patients versus 26% [95% CI: 17-36%] in non-DM patients. Hazard ratio (for matched pairs) was 1.15 (95% CI: 0.75-1.77; p = 0.51). Conclusions: DM did not adversely impact survival in patients with pancreatic cancer. Pancreatic cancer did not affect glycemic control. Elevated ca 19-9 in diabetic patients may be an unreliable marker for gauging disease progression.

scholarly journals Frequency of HLA-DRB1 Gene Alleles in Patients With Multiple Sclerosis in a Lithuanian Population

Medicina ◽  
2012 ◽  
Vol 48 (1) ◽  
pp. 2
Author(s):  
Renata Balnytė ◽  
Daiva Rastenytė ◽  
Dalia Mickevičienė ◽  
Antanas Vaitkus ◽  
Erika Skrodenienė ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Case Control Study ◽  
Case Control ◽  
Chain Reaction ◽  
Female Patients ◽  
History Of ◽  
Male Patients ◽  
Polymerase Chain ◽  
The Relationship ◽  
Control Study

The aim of the present study was to investigate the influence of HLA-DRB1 alleles on the genetic susceptibility to multiple sclerosis in the Lithuanian population. Material and Methods. A total of 120 patients with multiple sclerosis and 120 unrelated healthy controls were enrolled in this case-control study. Allelic frequencies were compared between the groups. HLA-DRB1 alleles were genotyped using the polymerase chain reaction. Results. HLA-DRB1*15 was present in 55.8% of the patients with multiple sclerosis and 10.0% of the controls (OR, 5.58; 95% CI, 3.19–9.77; P<0.0001). The protective alleles that were found to be more prevalent among the controls compared with the patients with multiple sclerosis were HLADRB1* 01 (26.7% vs. 7.5%, P<0.0001), *03 (17.5% vs. 8.3%, P=0.034), and *16 (11.7% vs. 3.3%, P=0.014). HLA-DRB1*15 was more common among the female patients with multiple sclerosis than among the male patients (68.4% vs. 34.1%; OR, 4.18; 95%, CI 1.90–9.22; P=0.001). The heterozygous inheritance of HLA-DRB1*15 allele was more common in the patients with a history of maternal multiple sclerosis than in those with a history of paternal multiple sclerosis (29.4% vs. 9.8%; P=0.045). Conclusions. HLA-DRB1*15 was found to be associated with multiple sclerosis in the Lithuanian population. This allele was more prevalent among the female patients with multiple sclerosis. Maternal multiple sclerosis was more common than paternal multiple sclerosis, but the relationship with HLA-DRB1*15 allele was not established. HLA-DRB1*01, *03, and *16 appeared to be the protective alleles in this series.

Family history of cancer and the risk of bladder cancer: A case–control study from Italy

2017 ◽  
Vol 48 ◽  
pp. 29-35 ◽  
Author(s):  
Federica Turati ◽  
Cristina Bosetti ◽  
Jerry Polesel ◽  
Diego Serraino ◽  
Maurizio Montella ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Family History ◽  
Case Control Study ◽  
Case Control ◽  
Family History Of Cancer ◽  
History Of ◽  
Control Study ◽  
History Of Cancer

scholarly journals Aspirin use is not associated with the risk or prognosis of bladder cancer: a case‐control study and meta-analytic assessment

2020 ◽  
Author(s):  
Bo Fan ◽  
Hong Luo ◽  
Hui dan Jin ◽  
Meng fan Sun ◽  
Man Sun ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cohort Study ◽  
Subgroup Analysis ◽  
Northeast China ◽  
Lower Risk ◽  
Case Control Study ◽  
Meta Analysis ◽  
Case Control ◽  
Male Patients ◽  
Control Study

Abstract Background Aspirin, widely used for the prevention of cardiovascular disease, could reduce the risk of many types of cancer, including colorectal, breast, and pancreatic cancer. Concerns have also been linked to bladder cancer(BCa), but relevant studies on the effects of aspirin on the occurrence or prognosis of BCa are inconsistent or even controversial. Meanwhile, existing studies focusing on Chinese populations are relatively uncommon, especially for Northeast China. Therefore, this study aims to assess the association of aspirin use with the occurrence and prognosis of BCa in Northeast China. Methods First, we investigated the association between aspirin use and BCa risk in a retrospective cohort study including 1087 patients with BCa from 2002 to 2019 and 1100 healthy persons in the same period as controls. Subsequently, we quantificationally combined the results with those from the published literature evaluating aspirin intake and its effects on the occurrence and prognosis of BCa by meta-analysis after searching the PubMed, Embase, Cochrane Library, and Google Scholar databases up to March 1, 2020. Results The results of our case-control study demonstrated that the regular use of aspirin was not associated with a reduced incidence of BCa (OR = 1.17, p = 0.311). Stratified analyses of sex showed that aspirin intake did not lead to a lower risk of BCa in male patients (OR = 1.25, p = 0.230) or in female patients (OR = 0.90, p = 0.744). Significant correlations were not found in the age subgroup analysis dividing age into younger or greater than 65, with a pooled OR estimate of 1.25 (p = 0.230) and 0.899 (p = 0.744). In 230 patients who relapsed from the 1087 BCa patients above, no significant relationship was found in the aspirin group (RR = 1.19, p = 0.360), and the sex stratification resulted in the same conclusion; however, in people younger than 68, aspirin seemed to have protective effects (RR = 0.60, p = 0.030). In addition, we performed a meta-analysis after searching several databases, and 10 articles involving 12441 BCa cases met the eligibility criteria, contributing to the analysis of aspirin intake and the incidence of BCa. The combined results indicated that aspirin intake was not associated with the occurrence of BCa (OR = 1.03, p = 0.221). In the subgroup analysis, aspirin intake did not reduce the risk of BCa in male patients (OR = 1.08, p = 0.163), female patients (OR = 0.92, p = 0.441), Asian patients (OR = 1.07; p = 0.088), European patients (OR = 1.12, p = 0.390), or North American patients (OR = 0.99, p = 0.839). At the same time, the study type did not influence the lack of a connection between aspirin intake and the risk of BCa in the cohort study (OR = 1.05; p = 0.176) and case-control study (OR = 1.01; p = 0.797). To explore the impact of aspirin intake on the prognosis of patents with BCa, 8 articles involving 3250 BCa cases were eligible. The combined results showed that patients with aspirin intake did not have a significantly lower risk of BCa recurrence than those without aspirin intake (HR = 0.94, p = 0.718), and a consistent conclusion was also reached for overall survival (HR = 1.04, p = 0.879) and cancer-specific survival (HR = 0.98, p = 0.980) by subgroup analysis. Conclusions Both our retrospective study and literature meta-analysis suggested a lack of a relevant association between the use of aspirin and the risk and prognosis of BCa. Thus, additional long-term follow-up prospective research is warranted to clarify the association of aspirin with BCa incidence and prognosis.

scholarly journals The impact of Alzheimer's disease on the loss of dental elements. Systematic review with meta-analysis of case control study

2019 ◽  
Vol 10 ◽  
Author(s):  
Mario Dioguardi ◽  
Giovanni Di Gioia ◽  
Marco Mascitti ◽  
Andrea Santarelli ◽  
Maurizio Procaccini ◽  
...  
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Case Control Study ◽  
Meta Analysis ◽  
Case Control ◽  
The Impact ◽  
Control Study

scholarly journals Parity, early menopause and the incidence of bladder cancer in women: A case–control study and meta-analysis

2011 ◽  
Vol 47 (4) ◽  
pp. 592-599 ◽  
Author(s):  
K. Dietrich ◽  
E. Demidenko ◽  
A. Schned ◽  
M.S. Zens ◽  
J. Heaney ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Case Control Study ◽  
Meta Analysis ◽  
Case Control ◽  
Early Menopause ◽  
Control Study

scholarly journals Personal Hygiene and the Risk of Leprosy: A Meta-Analysis from Case Control Study

2020 ◽  
Author(s):  
Priscilla Jessica Pihahey ◽  
◽  
Bhisma Murti ◽  
Yulia Lanti Retno Dewi ◽  
◽  
...  
Keyword(s):  
Odds Ratio ◽  
English Language ◽  
Case Control Study ◽  
Meta Analysis ◽  
Social Contact ◽  
Case Control ◽  
Personal Hygiene ◽  
Central Java ◽  
The Impact ◽  
Control Study

ABSTRACT Background: Leprosy is caused by Mycobacterium leprae (M. leprae) which is transmitted through nasal and oral fluids. The incubation period for M. leprae ranging from 3 years to 20 years. The impact of leprosy is a disability that reduces the quality of life. Social contact to patients can increase the risk of leprosy. This study aimed to determine the relationship between personal hygienic and the risk of leprosy. Subjects and Method: This was a meta-analysis and systematic review on the Leprosy determinants. This study was conducted by search published articles from PubMed, ProQuest, Science Direct, Scopus, Spinger Link, EBSCO, Google Scholar, Embase, LILACS, Embase, Emerald, PLOS, and Indonesian National Library (Perpusnas) electronic databases. “leprosy OR hansen desease AND risk factor AND Personal hygiene OR sanitation AND odds ratio” keywords were inserted to find related articles. The inclusion criteria were full text, open access article, published from 1949 to 2020, using Indonesian or English language, case control study, and reporting adjusted odds ratio (aOR). The articles were analyzed using PRISMA flow chart and Revman 5.3. Results: 4 articles were met the criteria. A sample of 297 cases and 297 controls was selected for this study. This study reported that poor personal hygiene increased the risk of Leprosy 3.52 times (aOR= 3.52; 95%CI= 2.30 to 5.40; p<0.001). Conclusion: Poor personal hygiene increases the risk of Leprosy. Keywords: personal hygiene, Leprosy, meta-analysis Correspondence: Priscilla Jessica Pihaheys. Masters Program in Public Health. Universitas Sebelas Maret, Jl. Ir. Sutami 36A, Surakarta 57126, Central Java. Email: [email protected]. Mobile: 08114852336. DOI: https://doi.org/10.26911/the7thicph.01.53

TNF-α gene polymorphisms and risk of urinary bladder cancer – A case-control study and meta-analysis

Meta Gene ◽  
2021 ◽  
pp. 100848
Author(s):  
Prashant Tripathi ◽  
Rajender Singh ◽  
Alok Raghav ◽  
Satya Narayan Sankhwar ◽  
Sandeep Kumar Bansal ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Gene Polymorphisms ◽  
Case Control Study ◽  
Meta Analysis ◽  
Urinary Bladder Cancer ◽  
Case Control ◽  
Tnf Α ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document